🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07489612
Enrolling by invitation Phase 2

QLS1410 in Participants With Uncontrolled Hypertension

NCT07489612 · tracked via the Priya Life Science China tracker
Sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 2
Started
2026-04
Last updated
2026-05-22

Condition(s) studied

Hypertension (HTN)

Investigational drug(s) / intervention(s)

Dose 1 of QLS1410Dose 2 of QLS1410Dose 3 of QLS1410placebo

Dose 1 of QLS1410: QLS1410 tablet administered orally, once daily (QD).

Dose 2 of QLS1410: QLS1410 tablet administered orally, once daily (QD).

Dose 3 of QLS1410: QLS1410 tablet administered orally, once daily (QD).

placebo: Matching placebo tablet administered orally, once daily (QD).

Study summary

The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure(SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Male or female participants must be ≥ 18 years old. 2. Mean seated SBP ≥ 140 mmHg at Screening and at Baseline.. 3. Fulfil at least 1 of the following 2 criteria: * Uncontrolled Hypertension (uHTN) subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator. * Resistant Hypertension (rHTN) subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator. Exclusion Criteria: 1. Mean seated systolic blood pressure (SBP)≥ 180 mmHg. 2. Mean seated diastolic blood pressure (DBP)≥ 110 mmHg. 3. Estimated glomerular filtration rate \< 45 mL/min/1.73m2. 4. Serum potassium (K+) level \<3.5 and ≥ 5.0 mmol/L. 5. Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation. 6. NYHA functional heart failure class IV at Screening.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Qilu Hospital of Shandong University Jinan China

More Qilu Pharmaceutical Co., Ltd. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07489612 on ClinicalTrials.gov ↗ ← All trials in China